依那普利叶酸片与依那普利片预防高血压患者卒中的药物经济学评价 点击下载
论文标题: 依那普利叶酸片与依那普利片预防高血压患者卒中的药物经济学评价
英文标题:
中文摘要: 目的:对依那普利叶酸片与依那普利片用于高血压患者卒中预防的药物经济性进行评价。方法:使用Excel2016软件构建马尔可夫模型,选择原发性高血压患者作为研究对象,研究时限为20年,循环周期为1年。从卫生体系角度出发,使用成本-效用分析法对依那普利叶酸片与依那普利片用于高血压患者卒中预防的药物经济性进行比较,并用敏感性分析验证研究结果的稳健性。结果:与依那普利片相比,依那普利叶酸片的增量成本-效果比为221323.04元/质量调整生命年,大于3倍2020年中国人均国内生产总值(217341元)。单因素敏感性分析与概率敏感性分析的结果与基础分析的结果一致。结论:对于高血压患者而言,使用依那普利叶酸片预防卒中相较于依那普利片不具有经济性。
英文摘要: OBJECTIVE:To evaluate the pharmacoec onomics of Enalapril folic acid tablet and Enalapril tablet for stroke prevention in patients with hypertension. METHODS :Markov model was constructed by using Excel 2016 software. Patients with essential hypertension were selected as the research object with 1 year cycle and 20 years horizon. From the perspective of health system,the pharmacoeconomics of Enalapril folic acid tablets versus Enalapril tablets for stroke prevention in patients with hypertension was compared by cost-effectiveness analysis ,and the stability of the research results was verified by sensitivity analysis. RESULTS :Compared with Enalapril tablet ,the incremental cost-effectiveness ratio of Enalapril folic acid tablet was 221 323 yuan/QALY,which was higher than three times of China ’s per capita GDP in 2020(217 341.04 yuan). The results of single factor sensitivity analysis and probabilistic sensitivity analysis were consistent with that of basic analysis. CONCLUSIONS : Compared with Enalapril tablet ,Enalapril folic acid tablet doesn ’t have a better economy for patients with hypertension.
期刊: 2021年第32卷第23期
作者: 任宇,管欣,张瑶,马爱霞
英文作者: REN Yu ,GUAN Xin ,ZHANG Yao ,MA Aixia
关键字: 预防;卒中;药物经济学;依那普利叶酸片;依那普利片;高血压;卫生体系
KEYWORDS: Prevention;Stroke;Pharmacoeconomics;Enalapril folic acid tablet ;Enalapril tablet ;Hypertension;Health system
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!